Why the study?
Does alagebrium improve cardiovascular function in patients with aging-related cardiovascular disorders?
Does alagebrium improve cardiovascular function in patients with aging-related cardiovascular disorders?
Alagebrium, an advanced glycation end-product cross-link breaker, shows promise in improving arterial compliance and cardiac function in aging-related cardiovascular pathologies.
No takes yet. Share an insight, caveat, or question.
Alagebrium warrants no practice change; leaves open phase 3 confirmation of arterial and cardiac benefits in aging.
Bakris et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: